1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD.TO
Gilead Sciences, Inc.CA flagToronto Stock Exchange
29.19
CAD
-0.56
- -
251.60BMarket Cap
Gilead Sciences, Inc.
GILD.TO
(Toronto Stock Exchange)

Recent

price

29.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.7
0.81
0.96
1.1
2.45
3.35
3.41
3
2.56
2.65
2.95
3.26
3.26
3.26
3.46
3.55
3.68
Revenue per Share
0.25
0.27
0.26
0.3
1.19
1.86
1.51
0.53
0.63
0.64
0.01
0.74
0.55
0.68
0.06
1.03
-0.39
Basic EPS, GAAP
0.25
0.35
0.32
0.3
1.26
2.18
1.91
1.37
0.97
1.08
0.98
1.36
1.09
0.89
1.24
1.14
1.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.19
0.28
0.31
0.34
0.38
0.41
0.43
0.44
0.46
0.47
0.48
0.49
Dividend per Share
3.66
4.47
6.12
7.41
10.29
13.03
14.42
15.63
16.68
17.79
14.52
16.8
17.03
18.32
15.51
18.3
9.53
Book Value per Share
2.77
3.1
-2.3
-1.11
2.12
5
6.67
-0.62
1.2
3.65
-18.37
-16.52
-12.8
-9.58
-7.17
-2.09
-8.48
Tangible Book Value per Share
11,406
10,325
10,090
10,184
10,140
9,753
8,920
8,707
8,647
8,461
8,374
8,367
8,361
8,314
8,307
8,287
8,276
Basic Weighted Avg Shares
7,949
8,385
9,702
11,202
24,890
32,639
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
30,456
Sales/Revenue/Turnover
49.84
45.2
41.33
40.39
61.33
68
58.02
54.1
42.02
41.6
40.21
39.76
40.23
32.59
36.85
39.74
38.47
Operating Margin (%)
265
302
278
345
1,050
1,098
1,158
1,286
1,429
1,404
1,480
2,050
2,103
2,693
2,767
2,760
2,760
Depreciation Expense
2,901
2,804
2,592
3,075
12,101
18,108
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
-3,240
Net Income, GAAP
26.16
23.61
28.74
27.35
18.83
16.4
21.11
65.67
29.99
- -
94.67
25.09
21.47
18.18
30.58
13.13
37.84
Effective Tax Rate (%)
36.5
33.43
26.72
27.45
48.62
55.48
44.43
17.73
24.65
23.99
0.5
22.8
16.83
20.89
1.67
28.9
-10.64
Profit Margin (%)
3,243
11,404
1,918
590
11,953
14,872
10,370
20,188
25,231
20,537
4,599
3,162
3,205
4,805
7,169
6,529
2,925
Working Capital
2,839
7,606
7,055
3,939
11,921
21,073
26,346
30,795
24,574
22,094
28,645
25,179
22,957
23,189
24,896
22,129
23,832
LT Debt
6,122
6,867
9,544
11,745
15,819
19,113
19,363
20,501
21,534
22,650
18,221
21,064
21,209
22,749
19,246
22,618
11,744
Total Equity
33.67
24.36
17.96
18.43
53.74
54.43
32.6
9.75
12.67
- -
1.1
16.76
18.29
15.25
15.52
21.77
20.78
Return on Invested Capital (%)
34.48
24.71
17.79
18.35
53.55
53.85
32.86
10.02
12.06
- -
0.43
14.37
11.36
13.78
2.47
20.1
40.57
Return on Capital (%)
47.44
44.49
32.32
29.75
90.32
106.64
72.16
23.53
26.08
24.53
0.6
31.7
21.71
25.71
2.28
40.49
-20.57
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,807
1,313
2,414
LT Borrowings
22,129
20,861
23,832
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,241
1,242
1,241
Market Capitalization
- -
24,787
22,382

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
18,342
18,641
13,945
Cash, Cash Equivalents & STI
9,613
7,643
3,179
Accounts Receivable, Net
4,913
4,741
5,055
Inventories
1,774
1,914
1,953
Total Current Liabilities
11,813
9,475
11,020
Payables & Accruals
5,144
4,763
4,907
ST Debt
2,807
1,313
2,414
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.35%
5.13%
17.52%
Free Cash Flow
-4.97%
6.3%
-8.24%
Net Income, GAAP
636.72%
1,307.9%
1,672.92%
Sales/Revenue/Turnover
-0.64%
3.67%
2.39%
Total Cash Common Dividend
8.17%
3.03%
2.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,686
6,953
7,545
7,569
28,754
2025
6,667
7,081
7,769
7,924
29,442
2026
6,960
7,803
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.5
0.19
0.15
0.21
0.06
2025
0.16
0.24
- -
0.26
1.03
2026
0.24
-1.27
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.12
0.12
0.12
0.47
2025
0.12
0.12
- -
0.12
0.48
2026
0.13
0.12
- -
- -
- -
Similar Companies
Santen Pharmaceutical Co., Ltd. (SNPHY)
Biogen Inc. (IDP.DE)
Santen Pharmaceutical Co., Ltd. (SNPHF)
Eli Lilly and Company (LLY.DE)
SMS Pharmaceuticals Limited (SMSPHARMA.BO)
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS)
Business
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.